pertuzumab + gemcitabine

This is a combination regimen of **pertuzumab**, a humanized monoclonal antibody that targets and inhibits dimerization of human epidermal growth factor receptor 2 (**HER2**, also called ERBB2), and **gemcitabine**, a nucleoside analog chemotherapeutic agent that inhibits DNA synthesis, leading to cell death. Pertuzumab blocks HER2 heterodimerization, thereby disrupting downstream proliferative signaling in HER2-positive cancer cells, while gemcitabine acts as an antimetabolite interfering with DNA replication in rapidly dividing cells. The combination has been studied in **platinum-resistant ovarian cancer** and is in clinical trials for other HER2-positive malignancies, including breast cancer, aiming to overcome resistance and provide additive or synergistic antitumor effects[2][3].

Other names

pertuzumab and gemcitabinegemcitabine plus pertuzumab